Lab
Quest Diagnostics Clinical Laboratories INC
Quest Diagnostics Clinical Laboratories INC was paid $21.85M by Medicaid between Jan 2018 and Dec 2024, across 257 billing codes. Its largest line is 87491, Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe — 5.5% of everything it billed.
33Billing provider infoQUEST DIAGNOSTICS CLINICAL LABORATORIES INC
PORTLAND, OR 97230
PORTLAND, OR 97230
33aNPI1114963956assigned 06/21/2006
33bProvider typeClinical Medical Laboratory
28Total paid$21.85M
24GClaims1,578,051
24DCodes billed257
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Oregon
Rank by total paid#5 of 46
Median peer was paid$50K
This provider vs. median438×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official BOWLES, CHARLES controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 229,908 | $3.34M | |
| 2019 | 197,873 | $2.74M | |
| 2020 | 217,858 | $3.32M | |
| 2021 | 184,665 | $2.44M | |
| 2022 | 214,580 | $2.79M | |
| 2023 | 251,571 | $3.30M | |
| 2024incomplete | 281,596 | $3.91M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 5.5% | 55,624 | 45,809 | $1.21M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 5.5% | 55,530 | 45,775 | $1.21M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 5.1% | 15,919 | 15,284 | $1.11M |
| 81420 | Fetal chromosomal aneuploidy genomic sequence analysis panel | 4.3% | 1,946 | 1,929 | $937K |
| 80053 | Comprehensive metabolic panel | 4.2% | 136,309 | 132,900 | $907K |
| 80061 | Lipid panel | 3.7% | 96,499 | 95,228 | $802K |
| 84443 | Thyroid stimulating hormone (TSH) | 3.6% | 71,268 | 70,092 | $791K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 3.2% | 34,744 | 34,288 | $702K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.2% | 10,127 | 8,853 | $696K |
| 81513 | 2.9% | 6,743 | 6,631 | $635K | |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 2.8% | 26,494 | 25,706 | $605K |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.6% | 29,587 | 28,834 | $558K |
245 more codes
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | 2.5% | 11,425 | $541K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.5% | 13,273 | $536K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.4% | 31,577 | $525K |
| 83036 | Hemoglobin; glycosylated (A1C) | 2.4% | 84,657 | $514K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.1% | 95,924 | $468K |
| 87536 | 1.7% | 6,637 | $369K | |
| 87799 | 1.7% | 14,133 | $368K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 1.6% | 14,675 | $355K |
| 82728 | 1.6% | 38,048 | $350K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.5% | 7,842 | $329K |
| 86803 | 1.5% | 33,183 | $318K | |
| 86003 | 1.2% | 3,553 | $270K | |
| 84403 | 1.2% | 14,970 | $267K | |
| 86480 | <1% | 4,733 | $196K | |
| 82607 | <1% | 19,772 | $195K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 59,100 | $182K |
| 82670 | <1% | 8,649 | $169K | |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 457 | $168K |
| 80081 | <1% | 2,978 | $163K | |
| 83550 | <1% | 24,418 | $140K | |
| 84481 | <1% | 11,308 | $140K | |
| 84439 | <1% | 21,342 | $134K | |
| 87512 | <1% | 4,429 | $132K | |
| 80050 | General health panel | <1% | 3,145 | $130K |
| 87902 | <1% | 683 | $128K | |
| 82746 | <1% | 13,085 | $124K | |
| 88142 | <1% | 8,168 | $121K | |
| 87522 | Neg quan hep c or qual rna | <1% | 4,195 | $119K |
| 83013 | <1% | 2,534 | $116K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 21,148 | $108K |
| 83540 | <1% | 24,975 | $107K | |
| 87340 | <1% | 15,108 | $104K | |
| 86001 | <1% | 283 | $86K | |
| 84402 | <1% | 4,929 | $86K | |
| 86360 | <1% | 2,890 | $85K | |
| 88141 | <1% | 5,797 | $83K | |
| 87088 | <1% | 16,161 | $81K | |
| 86235 | <1% | 1,504 | $80K | |
| 86317 | <1% | 7,718 | $77K | |
| 84153 | <1% | 6,693 | $72K | |
| 84702 | <1% | 6,702 | $72K | |
| 86364 | <1% | 1,218 | $70K | |
| 80074 | <1% | 1,976 | $68K | |
| 86704 | <1% | 7,997 | $65K | |
| 86359 | <1% | 2,721 | $64K | |
| 84270 | <1% | 4,097 | $62K | |
| 83655 | <1% | 6,771 | $59K | |
| 83001 | <1% | 4,363 | $58K | |
| 86696 | <1% | 3,814 | $57K | |
| 84144 | <1% | 3,807 | $56K | |
| 86592 | <1% | 18,418 | $55K | |
| 83880 | <1% | 2,606 | $54K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 485 | $52K |
| 82043 | <1% | 15,930 | $52K | |
| 86376 | <1% | 4,916 | $52K | |
| 86038 | <1% | 6,226 | $51K | |
| 82570 | <1% | 17,701 | $51K | |
| 82627 | <1% | 3,130 | $50K | |
| 82652 | <1% | 1,803 | $49K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 10,294 | $48K |
| 86800 | <1% | 4,207 | $47K | |
| 86141 | <1% | 5,214 | $47K | |
| 83090 | <1% | 3,824 | $47K | |
| 84146 | <1% | 3,230 | $45K | |
| 85027 | <1% | 10,181 | $44K | |
| 86780 | <1% | 4,915 | $44K | |
| 83002 | <1% | 3,243 | $43K | |
| 83970 | <1% | 1,957 | $42K | |
| 87480 | <1% | 2,856 | $41K | |
| 87510 | <1% | 2,855 | $41K | |
| 87660 | <1% | 2,856 | $39K | |
| 87070 | <1% | 6,562 | $39K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,114 | $39K |
| 83516 | <1% | 4,748 | $39K | |
| 87186 | <1% | 7,281 | $38K | |
| 87338 | <1% | 3,741 | $36K | |
| 81511 | <1% | 376 | $36K | |
| 86695 | <1% | 3,534 | $36K | |
| 87077 | <1% | 7,261 | $35K | |
| 82274 | <1% | 3,562 | $35K | |
| 83921 | <1% | 2,781 | $35K | |
| 81329 | <1% | 371 | $33K | |
| 83520 | <1% | 3,151 | $33K | |
| 88342 | <1% | 736 | $33K | |
| 86708 | <1% | 3,695 | $32K | |
| 87209 | <1% | 2,575 | $32K | |
| 86665 | <1% | 1,244 | $31K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 65 | $31K |
| 88112 | <1% | 727 | $27K | |
| 86140 | <1% | 7,572 | $26K | |
| 82785 | <1% | 2,227 | $26K | |
| 87517 | <1% | 966 | $25K | |
| 82784 | <1% | 3,223 | $25K | |
| 82533 | <1% | 2,266 | $25K | |
| 82542 | <1% | 1,499 | $24K | |
| 86200 | <1% | 2,595 | $23K | |
| 83735 | <1% | 5,290 | $22K | |
| 83525 | <1% | 2,506 | $22K | |
| 86706 | <1% | 2,854 | $22K | |
| 82105 | <1% | 1,975 | $21K | |
| 82951 | <1% | 2,213 | $21K | |
| 83690 | <1% | 4,289 | $20K | |
| 87625 | <1% | 786 | $19K | |
| 87481 | <1% | 517 | $19K | |
| 80076 | <1% | 3,131 | $18K | |
| 86008 | <1% | 245 | $17K | |
| 86787 | <1% | 1,495 | $16K | |
| 87177 | <1% | 2,574 | $16K | |
| 83721 | <1% | 2,333 | $15K | |
| 84630 | <1% | 1,840 | $14K | |
| 85652 | <1% | 7,401 | $14K | |
| 86431 | <1% | 3,548 | $14K | |
| 86664 | <1% | 1,114 | $13K | |
| 81001 | <1% | 6,203 | $12K | |
| 82677 | <1% | 621 | $12K | |
| 82172 | <1% | 937 | $12K | |
| 86769 | <1% | 928 | $12K | |
| 86762 | <1% | 1,149 | $12K | |
| 87081 | <1% | 2,393 | $11K | |
| 87255 | <1% | 354 | $10K | |
| 85610 | <1% | 3,956 | $10K | |
| 86039 | <1% | 1,229 | $9K | |
| 83993 | <1% | 453 | $9K | |
| 82150 | <1% | 1,936 | $9K | |
| 86709 | <1% | 1,135 | $9K | |
| 84550 | <1% | 3,097 | $9K | |
| 86682 | <1% | 943 | $9K | |
| 82525 | <1% | 994 | $8K | |
| 82977 | <1% | 1,659 | $8K | |
| 82672 | <1% | 534 | $8K | |
| 84425 | <1% | 650 | $8K | |
| 87147 | <1% | 2,426 | $8K | |
| 84436 | <1% | 2,334 | $8K | |
| 82565 | <1% | 2,324 | $8K | |
| 86336 | <1% | 613 | $8K | |
| 81596 | <1% | 193 | $7K | |
| 85060 | <1% | 475 | $7K | |
| 80178 | <1% | 1,664 | $7K | |
| 84480 | <1% | 1,254 | $6K | |
| 84154 | <1% | 533 | $6K | |
| 82530 | <1% | 238 | $6K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 266 | $6K |
| 85730 | <1% | 1,570 | $6K | |
| 80164 | <1% | 808 | $6K | |
| 86705 | <1% | 748 | $6K | |
| 99001 | <1% | 2,000 | $6K | |
| 86160 | <1% | 394 | $6K | |
| 80069 | <1% | 1,223 | $5K | |
| 84165 | <1% | 909 | $5K | |
| 87631 | <1% | 60 | $5K | |
| 87427 | <1% | 578 | $5K | |
| 84482 | <1% | 387 | $5K | |
| 86225 | <1% | 464 | $4K | |
| 86765 | <1% | 470 | $4K | |
| 87075 | <1% | 748 | $4K | |
| 87205 | <1% | 1,519 | $4K | |
| 84156 | <1% | 1,793 | $4K | |
| 84207 | <1% | 165 | $4K | |
| 86735 | <1% | 405 | $4K | |
| 87045 | <1% | 596 | $4K | |
| 82550 | <1% | 935 | $4K | |
| 84100 | <1% | 1,441 | $4K | |
| 82330 | <1% | 486 | $3K | |
| 87449 | <1% | 491 | $3K | |
| 86663 | <1% | 378 | $3K | |
| 84479 | <1% | 863 | $3K | |
| 87529 | <1% | 74 | $3K | |
| 85007 | <1% | 1,200 | $3K | |
| 82248 | <1% | 956 | $3K | |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | <1% | 31 | $3K |
| 82040 | <1% | 825 | $3K | |
| 84681 | <1% | 208 | $3K | |
| 87046 | <1% | 401 | $3K | |
| 82950 | <1% | 739 | $3K | |
| 82397 | <1% | 194 | $2K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 896 | $2K |
| 83020 | <1% | 256 | $2K | |
| 87563 | <1% | 94 | $2K | |
| 83021 | <1% | 128 | $2K | |
| 86850 | <1% | 348 | $2K | |
| 85018 | <1% | 1,082 | $2K | |
| 85379 | <1% | 268 | $2K | |
| 86593 | <1% | 540 | $2K | |
| 86900 | <1% | 691 | $2K | |
| 82024 | <1% | 62 | $1K | |
| 86334 | <1% | 132 | $1K | |
| 86901 | <1% | 633 | $1K | |
| 84132 | <1% | 400 | $1K | |
| 82310 | <1% | 400 | $1K | |
| 85014 | <1% | 770 | $1K | |
| 88312 | <1% | 24 | $1K | |
| 84155 | <1% | 561 | $1K | |
| 86812 | <1% | 56 | $1K | |
| 81015 | <1% | 573 | $1K | |
| 87329 | <1% | 121 | $922.37 | |
| 85041 | <1% | 435 | $891.34 | |
| 88104 | <1% | 26 | $857.47 | |
| 86255 | <1% | 106 | $850.69 | |
| 83615 | <1% | 184 | $804.48 | |
| 84703 | <1% | 105 | $603.74 | |
| 86147 | <1% | 30 | $552.42 | |
| 84460 | <1% | 161 | $546.99 | |
| 87324 | <1% | 66 | $515.91 | |
| 84520 | <1% | 191 | $479.13 | |
| 85045 | <1% | 206 | $460.80 | |
| 82247 | <1% | 173 | $441.48 | |
| 86644 | <1% | 39 | $429.47 | |
| 81508 | <1% | 13 | $418.11 | |
| 82180 | <1% | 52 | $407.19 | |
| 86618 | <1% | 29 | $367.75 | |
| 82140 | <1% | 40 | $354.91 | |
| 86645 | <1% | 26 | $349.44 | |
| 82465 | <1% | 108 | $320.93 | |
| 84445 | <1% | 13 | $320.40 | |
| 82747 | <1% | 27 | $309.00 | |
| 82947 | <1% | 92 | $279.33 | |
| 82390 | <1% | 28 | $255.71 | |
| 83498 | <1% | 13 | $247.26 | |
| 86617 | <1% | 12 | $241.00 | |
| 88304 | <1% | 12 | $237.28 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,022 | $230.00 |
| 83695 | <1% | 943 | $225.90 | |
| 83704 | <1% | 850 | $209.76 | |
| 85004 | <1% | 49 | $194.79 | |
| 82679 | <1% | 13 | $174.70 | |
| 99199 | Unlisted special service, procedure or report | <1% | 2,536 | $174.69 |
| 84163 | <1% | 14 | $156.12 | |
| 84432 | <1% | 12 | $123.64 | |
| 87272 | <1% | 13 | $111.84 | |
| 84484 | <1% | 14 | $87.30 | |
| 85613 | <1% | 12 | $87.23 | |
| 84450 | <1% | 25 | $87.12 | |
| 85048 | <1% | 49 | $76.54 | |
| 83698 | <1% | 450 | $74.00 | |
| 87101 | <1% | 12 | $71.88 | |
| 80159 | <1% | 13 | $56.44 | |
| 81003 | <1% | 12 | $20.40 | |
| 80349 | 0% | 461 | $0.00 | |
| 80324 | 0% | 39 | $0.00 | |
| 80365 | 0% | 194 | $0.00 | |
| 80361 | 0% | 196 | $0.00 | |
| 80348 | 0% | 107 | $0.00 | |
| 80346 | 0% | 33 | $0.00 | |
| 81291 | 0% | 13 | $0.00 | |
| 80321 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBOWLES, CHARLES (VICE PRESIDENT)
Parent organizationQUEST DIAGNOSTICS INCORPORATED
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.